Fotivda
What Fotivda is used for
Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. Treatment of advanced renal cell carcinoma.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Fotivda
- Active substance
- tivozanib hydrochloride monohydrate
- Disease area
- Carcinoma, Renal Cell
- Medicine group
- Antineoplastic agents
- ATC code
- L01EK03
- Marketing authorisation holder
- Recordati Netherlands B.V.
- Authorised in the EU since
- 2017
Official information
In the USA
Same active substance: Fotivda
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Fotivda used for?
Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. Treatment of advanced renal cell carcinoma.
What is the active substance in Fotivda?
Fotivda contains tivozanib hydrochloride monohydrate.
Who makes Fotivda?
The EU marketing authorisation holder is Recordati Netherlands B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU